Spring Bank details peak HBV DNA and HBV RNA reductions for 100 mg dose of inarigivir

Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) reported data from 20 patients in the third cohort of Part A of Phase II ACHIEVE trial to treat chronic HBV infection showing that 100 mg inarigivir soproxil led to maximum reductions in HBV DNA and HBV RNA levels of 2.76 and 5 log₁₀, respectively.

Part A of the double-blind, placebo-controlled, international trial is evaluating once-daily 25, 50, 100 and 200 mg doses of inarigivir for 12 weeks followed by Viread tenofovir disoproxil fumarate monotherapy for 12 weeks in 80 patients with chronic HBV infection. Data from the 200 mg fourth dose cohort of inarigivir are expected by year end...